Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
3 - Onconetix, Inc. (0001782107) (Issuer)
4 - Onconetix, Inc. (0001782107) (Issuer)
4 - Onconetix, Inc. (0001782107) (Issuer)
8-K - Onconetix, Inc. (0001782107) (Filer)
DEF 14A - Onconetix, Inc. (0001782107) (Filer)
EFFECT - Onconetix, Inc. (0001782107) (Filer)
Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising
A leading AI and humanoid robotics company has commercially available models designed, built and manufactured in the United States of America CINCINNATI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc., (NASDAQ:ONCO) ("Onconetix" or the "Company"), (formerly Blue Water Biotech Inc), and Realbotix LLC. ("Realbotix"), a wholly-owned subsidiary of Realbotix Corp. (TSXV:XBOT) ("Realbotix Parent "), today announced the signing of a definitive share exchange agreement pursuant to which Onconetix will acquire 100% of the issued and outstanding equity interests of Realbotix in an all-stock transaction. Realbotix LLC is Realbotix Corp's subsidiary that is focused on researching, designing, bu
Realbotix Corp. (TSXV:XBOT) (Frankfurt: 76M0.F) (OTC:XBOTF) ("Realbotix" or the "Parent Company"), a leader in AI-powered humanoid robots, announces it has entered into a definitive agreement with Onconetix, Inc (NASDAQ:ONCO) ("ONCO"), pursuant to which ONCO will acquire 100% of Realbotix, LLC ("RealLLC" or the "Subsidiary"), a wholly owned subsidiary of Realbotix in an all-stock transaction. RealLLC is a Nevada based wholly owned subsidiary of Realbotix. RealLLC focuses on the research, development, design and manufacture of AI-powered humanoid robots for use by commercial clients in consumer facing roles such as customer service, healthcare, education, hospitality and entertainment. Rea
Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 7, 2025 /PRNewswire/ -- Equity Insider News Commentary – Major pharmaceutical companies presenting at the European Society for Medical Oncology Congress October 17-21[1] are unveiling pivotal survival data[2] and late-breaking lung cancer[3] results that demonstrate how diverse mechanisms are succeeding where traditional approaches stalled, while regulatory agencies issued multiple September approvals spanning gene therapies, bispecifics, and novel delivery systems[4]. The momentum reflects a fundamental shift as researchers discovered how cancer hijacks immune pathways to evade attack, spurring develop
SC 13G - Onconetix, Inc. (0001782107) (Subject)
SC 13D - Onconetix, Inc. (0001782107) (Subject)
SC 13D - Onconetix, Inc. (0001782107) (Subject)